APO Research
Talk to an analyst

APO RESEARCH · REPORT

Monoclonal Antibody Biologics and Biosimilars

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Monoclonal Antibody Biologics and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025196 pages

Choose your research edition.

Industry ResearchMonoclonal Antibody Biologics and Biosimilars Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Monoclonal Antibody Biologics and Biosimilars Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Monoclonal Antibody Biologics and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Monoclonal Antibody Biologics and Biosimilars Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Monoclonal Antibody Biologics and Biosimilars Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Monoclonal Antibody Biologics and Biosimilars market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Monoclonal Antibody Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Monoclonal Antibody Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Monoclonal Antibody Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Monoclonal Antibody Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Monoclonal Antibody Biologics and Biosimilars include Sanofi, Johnson & Johnson, Novartis, Merck, Roche, Eli Lilly, Pfizer, Biogen and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Monoclonal Antibody Biologics and Biosimilars market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Monoclonal Antibody Biologics and Biosimilars and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Monoclonal Antibody Biologics and Biosimilars revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Monoclonal Antibody Biologics and Biosimilars market size, projected growth trends, production technologies, key applications, and end-use industries.

Monoclonal Antibody Biologics and Biosimilars Segment by Company

Sanofi

Johnson & Johnson

Novartis

Merck

Roche

Eli Lilly

Pfizer

Biogen

Amgen

AbbVie

Sobi

Innovent Biologics

Celltrion

3SBIO

Monoclonal Antibody Biologics and Biosimilars Segment by Type

Biologics

Biosimilars

Monoclonal Antibody Biologics and Biosimilars Segment by Application

Cancer

Autoimmune Disease

Other

Monoclonal Antibody Biologics and Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Monoclonal Antibody Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Monoclonal Antibody Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Monoclonal Antibody Biologics and Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Monoclonal Antibody Biologics and Biosimilars in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Monoclonal Antibody Biologics and Biosimilars industry.

Chapter 3: Detailed analysis of Monoclonal Antibody Biologics and Biosimilars companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Monoclonal Antibody Biologics and Biosimilarsrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Biologics Table 3. Key Players of Biosimilars Table 4. Global Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Cancer Table 6. Key Players of Autoimmune Disease Table 7. Key Players of Other Table 8. Global Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 9. Global Monoclonal Antibody Biologics and Biosimilars Market Size by Region (2021-2026) & (US$ Million) Table 10. Global Monoclonal Antibody Biologics and Biosimilars Market Share by Region (2021-2026) Table 11. Global Monoclonal Antibody Biologics and Biosimilars Market Size by Region (2027-2032) & (US$ Million) Table 12. Global Monoclonal Antibody Biologics and Biosimilars Market Share by Region (2027-2032) Table 13. Monoclonal Antibody Biologics and Biosimilars Industry Trends Table 14. Monoclonal Antibody Biologics and Biosimilars Industry Drivers Table 15. Monoclonal Antibody Biologics and Biosimilars Industry Opportunities and Challenges Table 16. Monoclonal Antibody Biologics and Biosimilars Industry Restraints Table 17. Global Monoclonal Antibody Biologics and Biosimilars Revenue by Company (US$ Million) & (2021-2026) Table 18. Global Monoclonal Antibody Biologics and Biosimilars Revenue Market Share by Company (2021-2026) Table 19. Global Monoclonal Antibody Biologics and Biosimilars Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 20. Global Monoclonal Antibody Biologics and Biosimilars Key Company Head Office and Area Served Table 21. Global Monoclonal Antibody Biologics and Biosimilars Company, Product Type & Application Table 22. Global Monoclonal Antibody Biologics and Biosimilars Company Establishment Date Table 23. Global Company Market Concentration Ratio (CR5 and HHI) Table 24. Global Monoclonal Antibody Biologics and Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 25. Global Monoclonal Antibody Biologics and Biosimilars Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2021-2026) & (US$ Million) Table 27. Global Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2027-2032) & (US$ Million) Table 28. Global Monoclonal Antibody Biologics and Biosimilars Revenue Market Share by Type (2021-2026) Table 29. Global Monoclonal Antibody Biologics and Biosimilars Revenue Market Share by Type (2027-2032) Table 30. Global Monoclonal Antibody Biologics and Biosimilars Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2021-2026) & (US$ Million) Table 32. Global Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2027-2032) & (US$ Million) Table 33. Global Monoclonal Antibody Biologics and Biosimilars Revenue Market Share by Application (2021-2026) Table 34. Global Monoclonal Antibody Biologics and Biosimilars Revenue Market Share by Application (2027-2032) Table 35. Sanofi Company Information Table 36. Sanofi Business Overview Table 37. Sanofi Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Sanofi Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 39. Sanofi Recent Development Table 40. Johnson & Johnson Company Information Table 41. Johnson & Johnson Business Overview Table 42. Johnson & Johnson Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Johnson & Johnson Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 44. Johnson & Johnson Recent Development Table 45. Novartis Company Information Table 46. Novartis Business Overview Table 47. Novartis Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Novartis Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 49. Novartis Recent Development Table 50. Merck Company Information Table 51. Merck Business Overview Table 52. Merck Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Merck Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 54. Merck Recent Development Table 55. Roche Company Information Table 56. Roche Business Overview Table 57. Roche Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Roche Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 59. Roche Recent Development Table 60. Eli Lilly Company Information Table 61. Eli Lilly Business Overview Table 62. Eli Lilly Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Eli Lilly Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 64. Eli Lilly Recent Development Table 65. Pfizer Company Information Table 66. Pfizer Business Overview Table 67. Pfizer Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Pfizer Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 69. Pfizer Recent Development Table 70. Biogen Company Information Table 71. Biogen Business Overview Table 72. Biogen Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Biogen Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 74. Biogen Recent Development Table 75. Amgen Company Information Table 76. Amgen Business Overview Table 77. Amgen Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Amgen Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 79. Amgen Recent Development Table 80. AbbVie Company Information Table 81. AbbVie Business Overview Table 82. AbbVie Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. AbbVie Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 84. AbbVie Recent Development Table 85. Sobi Company Information Table 86. Sobi Business Overview Table 87. Sobi Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 88. Sobi Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 89. Sobi Recent Development Table 90. Innovent Biologics Company Information Table 91. Innovent Biologics Business Overview Table 92. Innovent Biologics Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 93. Innovent Biologics Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 94. Innovent Biologics Recent Development Table 95. Celltrion Company Information Table 96. Celltrion Business Overview Table 97. Celltrion Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 98. Celltrion Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 99. Celltrion Recent Development Table 100. 3SBIO Company Information Table 101. 3SBIO Business Overview Table 102. 3SBIO Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 103. 3SBIO Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 104. 3SBIO Recent Development Table 105. North America Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2021-2026) & (US$ Million) Table 106. North America Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2027-2032) & (US$ Million) Table 107. North America Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2021-2026) & (US$ Million) Table 108. North America Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2027-2032) & (US$ Million) Table 109. North America Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. North America Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021-2026) Table 111. North America Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2027-2032) Table 112. Europe Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2021-2026) & (US$ Million) Table 113. Europe Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2027-2032) & (US$ Million) Table 114. Europe Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2021-2026) & (US$ Million) Table 115. Europe Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2027-2032) & (US$ Million) Table 116. Europe Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. Europe Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021-2026) Table 118. Europe Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2027-2032) Table 119. China Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2021-2026) & (US$ Million) Table 120. China Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2027-2032) & (US$ Million) Table 121. China Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2021-2026) & (US$ Million) Table 122. China Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2027-2032) & (US$ Million) Table 123. Asia Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2021-2026) & (US$ Million) Table 124. Asia Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2027-2032) & (US$ Million) Table 125. Asia Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2021-2026) & (US$ Million) Table 126. Asia Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2027-2032) & (US$ Million) Table 127. Asia Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 128. Asia Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021-2026) Table 129. Asia Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2027-2032) Table 130. South America, Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2021-2026) & (US$ Million) Table 131. South America, Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2027-2032) & (US$ Million) Table 132. South America, Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2021-2026) & (US$ Million) Table 133. South America, Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2027-2032) & (US$ Million) Table 134. South America, Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 135. South America, Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021-2026) Table 136. South America, Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2027-2032) Table 137. Research Programs/Design for This Report Table 138. Authors List of This Report Table 139. Secondary Sources Table 140. Primary Sources List of Figures Figure 1. Monoclonal Antibody Biologics and Biosimilars Product Image Figure 2. Global Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Monoclonal Antibody Biologics and Biosimilars Market Share by Type: 2025 VS 2032 Figure 4. Biologics Image Figure 5. Biosimilars Image Figure 6. Global Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 7. Global Monoclonal Antibody Biologics and Biosimilars Market Share by Application: 2025 VS 2032 Figure 8. Cancer Image Figure 9. Autoimmune Disease Image Figure 10. Other Image Figure 11. Global Monoclonal Antibody Biologics and Biosimilars Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 13. Global Monoclonal Antibody Biologics and Biosimilars Market Share by Region: 2025 VS 2032 Figure 14. Years Considered Figure 15. Global Monoclonal Antibody Biologics and Biosimilars Market Share by Players in 2025 Figure 16. Global Top 5 and 10 Monoclonal Antibody Biologics and Biosimilars Players Market Share by Revenue in 2025 Figure 17. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Monoclonal Antibody Biologics and Biosimilars Revenue Market Share by Type (2021-2032) Figure 20. Global Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Monoclonal Antibody Biologics and Biosimilars Revenue Market Share by Application (2021-2032) Figure 22. North America Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 23. North America Monoclonal Antibody Biologics and Biosimilars Market Share by Type (2021-2032) Figure 24. North America Monoclonal Antibody Biologics and Biosimilars Market Share by Application (2021-2032) Figure 25. North America Monoclonal Antibody Biologics and Biosimilars Market Share by Country (2021-2032) Figure 26. United States Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 27. Canada Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 28. Mexico Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 29. Europe Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 30. Europe Monoclonal Antibody Biologics and Biosimilars Market Share by Type (2021-2032) Figure 31. Europe Monoclonal Antibody Biologics and Biosimilars Market Share by Application (2021-2032) Figure 32. Europe Monoclonal Antibody Biologics and Biosimilars Market Share by Country (2021-2032) Figure 33. Germany Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 34. France Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 35. U.K. Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 36. Italy Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 37. Russia Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 38. Nordic Countries Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 39. China Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 40. China Monoclonal Antibody Biologics and Biosimilars Market Share by Type (2021-2032) Figure 41. China Monoclonal Antibody Biologics and Biosimilars Market Share by Application (2021-2032) Figure 42. Asia Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 43. Asia Monoclonal Antibody Biologics and Biosimilars Market Share by Type (2021-2032) Figure 44. Asia Monoclonal Antibody Biologics and Biosimilars Market Share by Application (2021-2032) Figure 45. Asia Monoclonal Antibody Biologics and Biosimilars Market Share by Country (2021-2032) Figure 46. Japan Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 47. South Korea Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 48. Taiwan Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 49. Southeast Asia Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 50. India Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 51. Australia Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 52. South America, Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Share by Type (2021-2032) Figure 54. South America, Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Share by Application (2021-2032) Figure 55. South America, Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Share by Country (2021-2032) Figure 56. Brazil Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 57. South Africa Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 58. Saudi Arabia Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 59. Turkey Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 60. Argentina Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 61. UAE Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 62. Egypt Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 63. Chile Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 64. Research Process Figure 65. Key Executives Interviewed

Scope & coverage.

Types
  • Biologics
  • Biosimilars
Applications
  • Cancer
  • Autoimmune Disease
  • Other
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck
  • Roche
  • Eli Lilly
  • Pfizer
  • Biogen
  • Amgen
  • AbbVie
  • Sobi
  • Innovent Biologics
  • Celltrion
  • 3SBIO

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Biologics
  5. 1.2.3 Biosimilars
  6. 1.3 Market Analysis by Application
  7. 1.3.1 Global Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  8. 1.3.2 Cancer
  9. 1.3.3 Autoimmune Disease
  10. 1.3.4 Other
  11. 1.4 Global Market Growth Prospects
  12. 1.5 Global Monoclonal Antibody Biologics and Biosimilars Growth Trends by Region
  13. 1.5.1 Global Monoclonal Antibody Biologics and Biosimilars Market Size by Region: 2021 VS 2025 VS 2032
  14. 1.5.2 Monoclonal Antibody Biologics and Biosimilars Market Size by Region (2021-2026)
  15. 1.5.3 Monoclonal Antibody Biologics and Biosimilars Market Size by Region (2027-2032)
  16. 1.6 Assumptions and Limitations
  17. 1.7 Study Goals and Objectives
  18. 1.8 Years Considered
2 Global Monoclonal Antibody Biologics and Biosimilars Market Dynamics
  1. 2.1 Monoclonal Antibody Biologics and Biosimilars Industry Trends
  2. 2.2 Monoclonal Antibody Biologics and Biosimilars Industry Drivers
  3. 2.3 Monoclonal Antibody Biologics and Biosimilars Industry Opportunities and Challenges
  4. 2.4 Monoclonal Antibody Biologics and Biosimilars Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Monoclonal Antibody Biologics and Biosimilars Revenue by Company (2021-2026)
  2. 3.2 Global Monoclonal Antibody Biologics and Biosimilars Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Monoclonal Antibody Biologics and Biosimilars Key Company Head office and Area Served
  4. 3.4 Global Monoclonal Antibody Biologics and Biosimilars Company, Product Type & Application
  5. 3.5 Global Monoclonal Antibody Biologics and Biosimilars Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Monoclonal Antibody Biologics and Biosimilars Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Monoclonal Antibody Biologics and Biosimilars Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Monoclonal Antibody Biologics and Biosimilars Tier 1, Tier 2, and Tier 3
4 Monoclonal Antibody Biologics and Biosimilars Market by Type
  1. 4.1 Global Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2021-2032)
  3. 4.3 Global Monoclonal Antibody Biologics and Biosimilars Market Size Share by Type (2021-2032)
5 Monoclonal Antibody Biologics and Biosimilars Market by Application
  1. 5.1 Global Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2021-2032)
  3. 5.3 Global Monoclonal Antibody Biologics and Biosimilars Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Sanofi
  2. 6.1.1 Sanofi Company Information
  3. 6.1.2 Sanofi Business Overview
  4. 6.1.3 Sanofi Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Sanofi Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  6. 6.1.5 Sanofi Recent Developments
  7. 6.2 Johnson & Johnson
  8. 6.2.1 Johnson & Johnson Company Information
  9. 6.2.2 Johnson & Johnson Business Overview
  10. 6.2.3 Johnson & Johnson Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Johnson & Johnson Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  12. 6.2.5 Johnson & Johnson Recent Developments
  13. 6.3 Novartis
  14. 6.3.1 Novartis Company Information
  15. 6.3.2 Novartis Business Overview
  16. 6.3.3 Novartis Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Novartis Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  18. 6.3.5 Novartis Recent Developments
  19. 6.4 Merck
  20. 6.4.1 Merck Company Information
  21. 6.4.2 Merck Business Overview
  22. 6.4.3 Merck Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Merck Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  24. 6.4.5 Merck Recent Developments
  25. 6.5 Roche
  26. 6.5.1 Roche Company Information
  27. 6.5.2 Roche Business Overview
  28. 6.5.3 Roche Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Roche Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  30. 6.5.5 Roche Recent Developments
  31. 6.6 Eli Lilly
  32. 6.6.1 Eli Lilly Company Information
  33. 6.6.2 Eli Lilly Business Overview
  34. 6.6.3 Eli Lilly Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Eli Lilly Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  36. 6.6.5 Eli Lilly Recent Developments
  37. 6.7 Pfizer
  38. 6.7.1 Pfizer Company Information
  39. 6.7.2 Pfizer Business Overview
  40. 6.7.3 Pfizer Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Pfizer Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  42. 6.7.5 Pfizer Recent Developments
  43. 6.8 Biogen
  44. 6.8.1 Biogen Company Information
  45. 6.8.2 Biogen Business Overview
  46. 6.8.3 Biogen Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Biogen Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  48. 6.8.5 Biogen Recent Developments
  49. 6.9 Amgen
  50. 6.9.1 Amgen Company Information
  51. 6.9.2 Amgen Business Overview
  52. 6.9.3 Amgen Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Amgen Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  54. 6.9.5 Amgen Recent Developments
  55. 6.10 AbbVie
  56. 6.10.1 AbbVie Company Information
  57. 6.10.2 AbbVie Business Overview
  58. 6.10.3 AbbVie Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 AbbVie Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  60. 6.10.5 AbbVie Recent Developments
  61. 6.11 Sobi
  62. 6.11.1 Sobi Company Information
  63. 6.11.2 Sobi Business Overview
  64. 6.11.3 Sobi Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Sobi Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  66. 6.11.5 Sobi Recent Developments
  67. 6.12 Innovent Biologics
  68. 6.12.1 Innovent Biologics Company Information
  69. 6.12.2 Innovent Biologics Business Overview
  70. 6.12.3 Innovent Biologics Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Innovent Biologics Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  72. 6.12.5 Innovent Biologics Recent Developments
  73. 6.13 Celltrion
  74. 6.13.1 Celltrion Company Information
  75. 6.13.2 Celltrion Business Overview
  76. 6.13.3 Celltrion Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Celltrion Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  78. 6.13.5 Celltrion Recent Developments
  79. 6.14 3SBIO
  80. 6.14.1 3SBIO Company Information
  81. 6.14.2 3SBIO Business Overview
  82. 6.14.3 3SBIO Monoclonal Antibody Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 3SBIO Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  84. 6.14.5 3SBIO Recent Developments
7 North America
  1. 7.1 North America Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032)
  2. 7.2 North America Monoclonal Antibody Biologics and Biosimilars Market Size by Type
  3. 7.2.1 North America Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2021-2026)
  4. 7.2.2 North America Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2027-2032)
  5. 7.2.3 North America Monoclonal Antibody Biologics and Biosimilars Market Share by Type (2021-2032)
  6. 7.3 North America Monoclonal Antibody Biologics and Biosimilars Market Size by Application
  7. 7.3.1 North America Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2021-2026)
  8. 7.3.2 North America Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2027-2032)
  9. 7.3.3 North America Monoclonal Antibody Biologics and Biosimilars Market Share by Application (2021-2032)
  10. 7.4 North America Monoclonal Antibody Biologics and Biosimilars Market Size by Country
  11. 7.4.1 North America Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021-2026)
  13. 7.4.3 North America Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2027-2032)
  14. 7.4.4 North America Monoclonal Antibody Biologics and Biosimilars Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032)
  2. 8.2 Europe Monoclonal Antibody Biologics and Biosimilars Market Size by Type
  3. 8.2.1 Europe Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2021-2026)
  4. 8.2.2 Europe Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2027-2032)
  5. 8.2.3 Europe Monoclonal Antibody Biologics and Biosimilars Market Share by Type (2021-2032)
  6. 8.3 Europe Monoclonal Antibody Biologics and Biosimilars Market Size by Application
  7. 8.3.1 Europe Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2021-2026)
  8. 8.3.2 Europe Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2027-2032)
  9. 8.3.3 Europe Monoclonal Antibody Biologics and Biosimilars Market Share by Application (2021-2032)
  10. 8.4 Europe Monoclonal Antibody Biologics and Biosimilars Market Size by Country
  11. 8.4.1 Europe Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021-2026)
  13. 8.4.3 Europe Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2027-2032)
  14. 8.4.4 Europe Monoclonal Antibody Biologics and Biosimilars Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032)
  2. 9.2 China Monoclonal Antibody Biologics and Biosimilars Market Size by Type
  3. 9.2.1 China Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2021-2026)
  4. 9.2.2 China Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2027-2032)
  5. 9.2.3 China Monoclonal Antibody Biologics and Biosimilars Market Share by Type (2021-2032)
  6. 9.3 China Monoclonal Antibody Biologics and Biosimilars Market Size by Application
  7. 9.3.1 China Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2021-2026)
  8. 9.3.2 China Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2027-2032)
  9. 9.3.3 China Monoclonal Antibody Biologics and Biosimilars Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032)
  2. 10.2 Asia Monoclonal Antibody Biologics and Biosimilars Market Size by Type
  3. 10.2.1 Asia Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2021-2026)
  4. 10.2.2 Asia Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2027-2032)
  5. 10.2.3 Asia Monoclonal Antibody Biologics and Biosimilars Market Share by Type (2021-2032)
  6. 10.3 Asia Monoclonal Antibody Biologics and Biosimilars Market Size by Application
  7. 10.3.1 Asia Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2021-2026)
  8. 10.3.2 Asia Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2027-2032)
  9. 10.3.3 Asia Monoclonal Antibody Biologics and Biosimilars Market Share by Application (2021-2032)
  10. 10.4 Asia Monoclonal Antibody Biologics and Biosimilars Market Size by Country
  11. 10.4.1 Asia Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021-2026)
  13. 10.4.3 Asia Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2027-2032)
  14. 10.4.4 Asia Monoclonal Antibody Biologics and Biosimilars Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst